Welcome to our dedicated page for BlackRock Science and Technology Term Trust SEC filings (Ticker: BSTZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BlackRock Science and Technology Term Trust's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BlackRock Science and Technology Term Trust's regulatory disclosures and financial reporting.
Saba Capital Management and related reporting persons filed Amendment No. 10 to a Schedule 13D disclosing their beneficial ownership in BlackRock Science & Technology Term Trust. They report holding 5,458,908 common shares, representing 7.94% of the outstanding shares, based on 68,744,150 shares outstanding as of 12/31/25.
The position is held with shared voting and dispositive power across Saba Capital, Saba Capital Management GP, LLC and Boaz R. Weinstein. The filing states that approximately $93,845,617 was paid to acquire these shares using investor subscription proceeds, capital appreciation and ordinary-course margin borrowings. Recent transactions from 1/15/26 through 3/13/26 were executed in the open market.
BSTZ submitted an annual Form N-CEN reporting fund operational details for the period. The filing lists a monthly average value of portfolio securities on loan of 15,923,631.18 and net income from securities lending of 169,184. It also reports aggregate brokerage commissions of 1,090,390.38 and multiple principal-transaction totals including 1,015,069,082.85.
The form template contains many blank fields (registrant identifiers, director names, series identifiers and other administrative items) while providing item-level figures for securities lending, broker commissions and principal transaction values.
BlackRock Science and Technology Term Trust (BSTZ) delivered its certified shareholder report for the fiscal period ending 12/31/2025, including supplemental unaudited Section 19(a) notices and trust-level summaries.
The report discloses the Trust’s current monthly distribution of $0.162500 and an annualized distribution of $1.950000, showing a stated distribution rate of 8.62% on the closing market price of $22.61 as of 12/31/2025. It also notes a policy change effective 11/10/2025 that removed the options writing (overwrite) strategy from BSTZ’s principal investment strategies. The report includes portfolio positioning (33% semiconductors, 27% software, 21% hardware) and a top-holdings list led by Databricks and NVIDIA.
BlackRock Science & Technology Term Trust vice president Stephen Thomas Minar reported buying additional common shares of BSTZ. On February 10, 2026, he made several open‑market purchases at prices around $23.15 per share, including trades at $23.08 and $23.14.
After these transactions, Minar directly owned 8,074.209 shares of the trust’s common stock, indicating increased personal exposure to the fund.
BlackRock Science & Technology Term Trust portfolio manager Tony Kim reported buying additional common shares of BSTZ. On February 5, 2026, he purchased 41,525 shares at $22 per share and 300 shares at $21.96 per share. The filing shows directly owned positions of 251,554.3651 and 210,029.3651 common shares following the respective transactions.
BlackRock Science & Technology Term Trust (BSTZ) portfolio manager Tony Kim reported a mix of phantom share awards, conversions and a stock sale. On January 30, 2026, he received 20,534.0483 phantom shares, each economically equivalent to one common share and payable in cash as they vest over three years.
On the same date, 9,845.5493 and 5,734.6195 phantom shares were converted into the same number of common shares. Kim then sold 15,580.1688 common shares at $22.38 per share, leaving him with 208,712 common shares held directly after the sale.
Saba Capital Management and related reporting persons disclose a significant position in BlackRock Science & Technology Term Trust common shares. They report beneficial ownership of 4,682,590 common shares, representing 6.81% of the class, based on 68,744,150 shares outstanding as of 6/30/25. The shares are held with shared voting and dispositive power among Saba Capital, Saba Capital Management GP, LLC, and Boaz R. Weinstein.
Approximately $80,499,717 was paid to acquire these shares, using investor subscription proceeds, capital appreciation, and ordinary-course margin borrowings. The funds and accounts advised by Saba Capital are entitled to receive dividends and any sale proceeds from these shares. Recent transactions in the stock over the sixty days before 1/14/26 are detailed in an attached Schedule A.
BlackRock Science & Technology Term Trust reported an insider stock sale by one of its directors. The reporting person sold 9,293 shares of common stock on 12/18/2025 at a price of $22.51 per share. On 12/19/2025, the same person reported an additional sale of 0.6469 shares at $22.73 per share. After these transactions, the filing shows the director beneficially owning 0 shares of the trust’s common stock in direct ownership.